Navigation Links
Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
Date:11/9/2010

DURHAM, N.C., Nov. 9, 2010 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present on the potential of Argos' Arcelis™ immunotherapy as an innovative and effective treatment for HIV at the APHA 138th Annual Meeting & Exposition in Denver, Colo., at 1:45 p.m. MST on Wednesday, Nov. 10. The conference will take place at the Colorado Convention Center.

Data from a Phase 2a trial of Argos' Arcelis HIV program, AGS-004, demonstrated a significant reduction in viral load and a delay in viral rebound kinetics during a 12-week antiretroviral treatment interruption (ARTI) when compared to pre-ART viral loads. AGS-004 is currently being tested in a double-blind, placebo controlled, randomized Phase 2b study co-funded by the NIH to further demonstrate that it is a feasible treatment option of HIV-1 infected patients.

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argo
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
2. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
3. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
4. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
5. Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca® and Stretta® Systems
6. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
7. Nektar Therapeutics Reports Third Quarter 2010 Financial Results
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
10. Talecris Biotherapeutics Launches PROLASTIN®-C in Canada
11. Cell Therapeutics Awarded $977,917 in Grants Under the Therapeutic Discovery Tax Credit Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... and NOTTINGHAM, England , ... CBRX ) today announced that its subsidiary, Molecular ... Clinical Trials platform at the annual CPhI/ICSE Worldwide event ... aims to support companies with the rapid development of ... new enabling technologies screening platform, which incorporates the company,s ...
(Date:10/1/2014)... and NEW YORK , October 1, ... Research Organization (CRO) and service provider for the medical industries, announced ... of offices in New York City . genae ... City is strategically centered in one of the highest ... Coast", said Philippe Kassab , President at genae Americas. "The ...
(Date:10/1/2014)... 1, 2014 Trovagene, Inc., (NASDAQ:  TROV) ... that Eli Diamond , MD, Assistant Attending ... presented clinical data from an ongoing study demonstrating ... for the determination of oncogene mutational status in ... results were presented to both treating physicians and ...
Breaking Medicine Technology:Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3genae Opens Offices in New York City 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... Roper Industries, Inc. (NYSE: ROP ) ... (CUSIP No. 776696AA4) (the "Notes") will accrue contingent interest for ... at an annual rate of 0.25% of the average market ... January 12, 2011. Contingent cash interest, which the Company has ...
... 18, 2011 Soligenix, Inc. (Soligenix or the ... a late-stage biopharmaceutical company, announced today promising preliminary ... beclomathasone dipropionate or BDP) in a canine gastrointestinal ... that dogs treated with SGX202 demonstrated statistically significant (p=0.04) ...
Cached Medicine Technology:Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 2Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 3Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 4Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 5
(Date:10/1/2014)... strongly associated with Alzheimer,s disease; however, researchers are still ... causal agent of the onset and development of the ... beta-amyloid is not harmful when found in isolation but ... to form the so-called amyloid fibrils , "We are ... with multiple ones because each aggregate of peptide, which ...
(Date:10/1/2014)... 1, 2014 Patients with increased inflammation, including ... greatly increased risk of depression. For example, a ... hepatitis C virus infection causes depression in approximately ... more commonly known as fish oil, have a ... risk of heart disease and reducing triglyceride levels. ...
(Date:10/1/2014)... October 01, 2014 Insuranceragents.info has ... a good life insurance plan for vulnerable family members. ... vulnerable family members. Providers in the family should always ... cause financial hardships for the rest of the family. ... policies. Families can benefit more from temporary coverage or ...
(Date:10/1/2014)... ATLANTA (PRWEB) October 01, 2014 ... executive networking and relationship-marketing firm, announced today ... Security Executive® and Project of the Year ... decision makers representing organizations in financial services, ... include large-scale technology endeavors that address key ...
(Date:10/1/2014)... 01, 2014 Between 23 million and ... U.S., according to figures from the National Institutes of ... (AARDA), and many of them have something else in ... undiagnosed celiac disease. Gluten Free Therapeutics, makers of ... undiagnosed celiac disease by publishing a series of blog ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... , , , ... BMR ), The Leading Provider of Real Estate to the Life Science ... ring The Closing Bell(R) at the New York Stock Exchange on Thursday, ... anniversary of the company,s initial public offering. The ceremony will take place ...
... Tinnitus Sufferer ... ... of a deep-sleep to a high pitch ringing sound in your ear, or constantly hearing ... reality for millions of men and women who suffer from the medical condition tinnitus, often ...
... ... marketplace. , ... FL (PRWEB) August 6, 2009 -- Because prices and benefits for Medicare Supplement (Medigap) ... rates offered by GetOnlineQuotes.com are an affordable and viable option for those 65 and ...
... August 6, 2009 Comprehensive health reform proposals now before ... young adults ages 19-29 gain coverage, and such reforms ... coverage would not lose it, according to a new ... Americans through expansions in Medicaid and a health insurance ...
... Addison, TEXAS, Aug. 5 U L URU ... today announced that it has scheduled a conference call to discuss the second ... on Monday, August 17, 2009 at 9:00 a.m. Eastern Time. , , ... international callers dial (850) 429-1388 (access code 23453#) five to ten minutes prior ...
... , , MENLO PARK, Calif., ... announced that it has provided written notice to The NASDAQ Stock ... stock from the NASDAQ Global Market. The Company currently anticipates that, ... the Securities and Exchange Commission and NASDAQ a Form 25 relating ...
Cached Medicine News:Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 2Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 3Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 4Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 5Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 6Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 7Health News:Lipo-Flavonoid Launches New Video Testimonial 2Health News:Lipo-Flavonoid Launches New Video Testimonial 3Health News:GetOnlineQuotes.com to Offer AARP/United Healthcare Medicare Supplement Insurance to Florida Residents 2Health News:Health reform proposals could help 13 million uninsured young adults gain coverage 2Health News:Health reform proposals could help 13 million uninsured young adults gain coverage 3Health News:ULURU Inc. Announces Conference Call to Discuss Financial Results for the Second Quarter Ended June 30, 2009 and to Provide a Business Update 2Health News:XTENT Announces Plan for NASDAQ Delisting and Filing of Certificate of Dissolution 2
BB Watchmaker Forceps, Pakistan, 4.5" fine point....
The vertebral body replacement (VBR) is used for the anterior thoracic and lumbar spine. It is intended for use in the thoracic and lumbar spine to replace a collapsed, damaged, or unstable vertebral...
Vertigraft femoral shaft an large femoral cross-section designed primarily for use in lumbar corpectomy procedures. Freeze dried preservation....
... system provides anterior column support for single ... T1 to L5. The system consists of ... cages that are stacked to a desired ... Carbon fiber reinforced polymer material emulates the ...
Medicine Products: